Kisspeptin-54 for IVF Oocyte Maturation — Reproduction
Kisspeptin-54 as an investigational oocyte maturation trigger in IVF — Grade B evidence from multiple Phase 2 RCTs (n=175+ women, 95–96% maturation rate, 45% live birth rate, 33.6× lower OHSS risk vs hCG). Not FDA-approved; investigational use only in specialized fertility centers.
Overview
Kisspeptin is an endogenous hypothalamic neuropeptide encoded by the KISS1 gene, acting as the master regulator of the hypothalamic–pituitary–gonadal (HPG) axis. Kisspeptin-54 (the 54-amino acid form) has been studied as an oocyte maturation trigger in IVF, exploiting its ability to induce a physiological, self-limiting LH surge via GnRH neuron activation. Unlike hCG (which produces sustained luteotropic stimulation), kisspeptin's short half-life (~28 min) creates a LH pulse that mirrors the natural mid-cycle surge, dramatically reducing ovarian hyperstimulation syndrome (OHSS) risk. Phase 2 RCTs at Imperial College London (Hammersmith Hospital IVF Unit) established 95–96% oocyte maturation rates and ~45% live birth rates in high-responder populations, with a 33.6× lower OHSS risk compared to hCG. The double-dose protocol (second kisspeptin-54 injection 10h after the first) further improves oocyte yield in high-OHSS-risk patients. Kisspeptin remains investigational and is not commercially available; all published trials used IV or SC kisspeptin-54 produced under GMP conditions at Imperial College.
Indications
- IVF oocyte maturation trigger (investigational, Phase 2 evidence)
- High OHSS-risk IVF patients (polycystic ovarian morphology, high AFC, prior OHSS)
- Women for whom GnRH agonist trigger is contraindicated (non-freeze-all antagonist cycles)
- Reproductive hormone axis assessment (kisspeptin-10 IV challenge test)
- Low libido / hypogonadotropic hypogonadism — HPG axis stimulation (kisspeptin-10, Grade C)
Mechanism of Action
Kisspeptin-54 binds KISS1R (GPR54) on hypothalamic GnRH neurons, activating Gq/11 signaling cascade
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Kisspeptin-54 | 9.6 nmol/kg SC | Single dose, 36h before oocyte retrieval | Optimal dose from Abbara et al. 2020 Phase 2 RCT. Adjust for body weight. |
| Kisspeptin-54 | 9.6 nmol/kg SC × 2 | Two doses 10h apart, retrieval 36h after first dose | Abbara et al. 2021: 71% vs 45% achieving ≥60% oocyte maturation (p=0.042) vs single dose. |
| Kisspeptin-54 | 1.6–12.8 nmol/kg IV | Single dose (investigational dose-ranging) | Jayasena et al. 2014: 96% oocyte maturation at doses ≥6.4 nmol/kg IV. |
| Kisspeptin-10 | 100–200 mcg SC | Intermittent; 1–3× per week | No RCT evidence for libido indication. Monitor LH, testosterone, estradiol. Not commercially available. |
Evidence Grade
GRADE B
Safety & Contraindications
- Not FDA-approved and not commercially available — use restricted to specialized research and fertility centers
- Mild injection-site reactions (SC) and transient facial flushing reported; no severe adverse events in published trials
- Luteal phase support required after kisspeptin trigger (standard progesterone supplementation) — similar to GnRH agonist trigger
- Potential luteal phase insufficiency in non-freeze-all cycles: freeze-all embryo strategy recommended to mitigate risk
- Do not use in women with known KISS1R mutations or central hypogonadism secondary to KISS1/KISS1R loss-of-function
- Limited data in non-IVF fertility indications — off-label extrapolation is speculative
- Monitor LH and estradiol 4–6h post-trigger to confirm adequate surge